newsfilter
← Latest News
GlobeNewswire·

Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting